Characteristics of mRNA COVID-19 Vaccines Available in Saskatchewan Pharmacies

SHA has Vaccine Comparison tables that include additional COVID-19 vaccines available in General Vaccine Information.

By Vaccine Manufacturer

 

Pfizer-BioNTech 
Comirnaty®
Orange Cap, 
Orange Border

Pfizer-BioNTech 
Comirnaty®
Purple Cap,
Purple Border

Pfizer-BioNTech 
Comirnaty®
Grey Cap, 
Grey Border

Pfizer-BioNTech 
Comirnaty® Original & Omicron BA.4/BA.5
Grey Cap, Grey Border

DILUTE BEFORE USE  DO NOT DILUTE  
mRNA Vaccine Type Original Bivalent
Authorized Ages ≥ 5 Years to < 12 Years ≥12 Years 
Concentration 10 mcg / 0.2 mL 30 mcg / 0.3 mL  30 mcg / 0.3 mL
(15 mcg each Original and Omicron BA.4/BA.5) 
DIN 02522454 02509210 02527863 02531461
Packaging

Multidose preservative-free vials containing 10 doses

Cartons of 10 and 195 vials

Orange cap; orange border on label

Multidose preservative-free vials containing 6a doses

Cartons of 25 and 195 vials

Purple cap; purple border on label

Multidose preservative-free vials containing 6a doses

Cartons of 10 and 195 vials

Grey cap; grey border on label 

Multidose preservative-free vials containing 6a doses

Cartons of 10 vials

Grey cap; grey border on label 

Storage/Stability

Pfizer-BioNTech 
Comirnaty®
Orange Cap, 
Orange Border

Pfizer-BioNTech 
Comirnaty®
Purple Cap,
Purple Border

Pfizer-BioNTech 
Comirnaty®
Grey Cap, 
Grey Border

Pfizer-BioNTech 
Comirnaty® Original & Omicron BA.4/BA.5
Grey Cap, Grey Border
Stability in Freezer

Store at -90°C to -60°C (ultrafreezer) for up to 12 months from date on label. (Formerly 9 months)

Date on label is the date of manufacture.

Do not store at -25°C to -15°C.

Store at -90°C to -60°Cb (ultrafreezer) until the expiry date printed on the label. These dates have been extended for some product.c

Store at -25°C to -15°C for up to 2 weeks.d 

Store at -90°C to -60°C (ultrafreezer) for up to 12 months from date on label.

Date on label is the date of manufacture.

Do not store at -25°C to -15°C.
Thawing

Thaw undiluted product in fridge (takes up to 4 hours)
or
Thaw undiluted product at room temperature (takes ~30 minutes)

Do not refreeze thawed vials.

Thaw undiluted product in fridge (takes up to 3 hours)
or
Thaw undiluted product at room temperature (takes ~30 minutes)

Do not refreeze thawed vials.

Thaw in fridge (takes up to 6 hours)
or
Thaw at room temperature (takes ~30 minutes)

Do not refreeze thawed vials.

Stability in Refrigerator
(2°C to 8°C)

Undiluted product: up to 10 weeks

Undiluted product: up to 31 days

Up to 10 weeks prior to first use 
Dilution

Dilute thawed vials once they have reached room temperature with 1.3 mL of sterile 0.9% Sodium Chloride Injection, USP.

Dilute thawed vials once they have reached room temperature with 1.8 mL of sterile 0.9% Sodium Chloride Injection, USP.

DO NOT DILUTE  

Stability at Room Temperature (up to 25°C)

Prior to dilution, no more than 12 hours 

After dilution, use within 12 hours from time of dilution.e  

(Time is additive: up to 24 hours at room temperature)

Prior to dilution, no more than 2 hours (including any thaw time)

After dilution, use within 6 hours from time of dilution.

(Time is additive: up to 8 hours at room temperature)

Prior to puncture, no more than 12 hours

After puncture, use within 12 hours of puncture.f

 (Time is additive: up to 24 hours at room temperature) 

Prior to puncture, no more than 12 hours

After puncture, use within 12 hours of puncture.

 (Time is additive: up to 24 hours at room temperature)

Stability after
1st Puncture
Up to 12 hours at 2°C to 25°Cf Up to 6 hours at 2°C to 25°C 

Up to 12 hours at 2°C to 25°C f 

Up to 12 hours at 2°C to 25°C

Protect from Light

Store in original carton.

Vials can be handled in room light conditions after dilution.

Store in original carton.

Thawed vials can be handled in room light conditions.

Handling

Invert gently 10 times during reconstitution.
Do not shake.

Before use, mix by inverting vaccine vial gently 10 times.
Do not shake.

Appearance

BEFORE dilution: thawed suspension may contain white to off-white opaque amorphous particles.

AFTER dilution: white to off-white suspension; ensure no particulate matter/discolouration.

BEFORE dilution: thawed suspension may contain white to off-white opaque amorphous particles.

AFTER dilution: off-white suspension; ensure no particulate matter/ discolouration.

BEFORE inverting: may contain white to off-white opaque amorphous particles.

AFTER inverting: white to off-white suspension; ensure no visible particles/ discolouration.

Clinical Information
Pfizer-BioNTech 
Comirnaty™
Orange Cap, 
Orange Border
Pfizer-BioNTech 
Comirnaty™
Purple Cap,
Purple Border
Pfizer-BioNTech 
Comirnaty™
Grey Cap, 
Grey Border

Pfizer-BioNTech 
Comirnaty™ Original & Omicron BA.4/BA.5
Grey Cap, Grey Border
 

Dosage for Primary Series 0.2 mL (10 mcg mRNA) 0.3 mL (30 mcg mRNA)  

This vaccine is not authorized to be used as a primary COVID-19 immunization series. However, the SK Ministry of Health supports permissive administration of bivalent vaccines for this purpose, with informed consent, if an individual requests to start or complete their COVID-19 primary series with bivalent vaccine.

See information for original vaccines in the Saskatchewan Immunization Manual for details of intervals.

#Doses in Primary Series

Number of doses to complete the primary series:
2 for non-immunocompromised; 3 for immunocompromised

Minimum Interval Between 1st and 2nd Doses (used to determine validity) 19 days per NACI   
Authorized  Interval Between 1st and 2nd Doses 21 days    
MoH Minimum Interval Between 1st and 2nd Doses 28 days (21 days is acceptable)  
Optimal Interval

The optimal interval between 1st and 2nd doses per NACI and MoH is 8 weeksg 

Booster Doses Find information about doses, eligibility and intervals here.
Route of Administration Intramuscular (deltoid preferred)      
MoH = Ministry of Health; NACI = National Advisory Committee on Immunization

a. Six doses can be achieved by using low dead-volume syringes and/or needles. If standard syringes and needles are used, there may not be sufficient volume to extract 6 full doses from a single vial. 

b. On August 27, 2021, Health Canada expanded the Ultra Low Temperature storage conditions to now allow storage at -90°C to -60°C (-130°F to -76°F) versus the previously approved -80°C to -60°C (-112°F to -76°F). All references to storage conditions of -80°C to -60°C (-112°F to -76°F) on cartons and supporting printed material currently in Canada should now be considered between -90°C to -60°C (-130°F to -76°F.

c. Extensions to expiry dates for Pfizer-BioNTech Comirnaty® Purple Cap only (not Orange Cap or Grey Cap), as long as all approved storage conditions have been maintained, include:

  • Products with labelled expiry date of Jun 2022 through August 2022 may remain in use for 3 months beyond printed date.
Printed Expiry Date Updated Expiry Date
August 2022 November 2022

d. Vials stored/transported at -25°C to -15°C for up to 2 weeks may be returned (once) to the recommended storage condition of -90°C to -60°C. Total time the vials are stored and /or transported at -25°C to -15°C must be tracked and not exceed 2 weeks.

e. Vial labels and cartons may state that a vial should be discarded 6 hours after dilution; however, additional testing has been completed to support 12 hours of stability after dilution.

f. Vial labels and cartons may state that a vial should be discarded 6 hours after puncture; however, additional testing has been completed to support 12 hours of stability after puncture.

g. There is evidence that longer intervals between the first and second doses of COVID-19 vaccines result in a more robust and durable immune response and higher vaccine effectiveness. Local transmission of the SARS-CoV-2 virus, the degree of individual risk of exposure to the virus, and the need of a second dose for earlier protection should be considered when deciding the interval. People who completed their primary vaccine series using manufacturer-authorized intervals also have very good protection against severe COVID-19 disease and do not need to restart their vaccine series.

References
Last updated

01 Nov 2022

 

Moderna Spikevax™
Red Cap,
Blue Border

Moderna Spikevax™ Bivalent
Royal Blue Cap,
Green Border

DO NOT DILUTE  
mRNA Vaccine Type Original Bivalent
Authorized Ages ≥ 6 Years ≥ 18 Yearsa
Concentration 100 mcg / 0.5 mL 50 mcg / 0.5 mL
(25 mcg each Original and Omicron BA.1)
DIN 02510014 02530252
Packaging

Multidose preservative-free 5 mL vials

Cartons of 10 vials

Red cap; blue border on label

Multidose preservative-free 2.5 mL vials

Cartons of 10 vials

Royal blue cap; green border on label

Storage/Stability
Moderna Spikevax™
Red Cap,
Blue Border
Moderna Spikevax™ Bivalent
Royal Blue Cap,
Green Border
Stability in Freezer Store at -50°C to -15°C (freezer) until the expiry date printed on the label.  Store at -50°C to -15°C (freezer) until the expiry date printed on the label. 
Thawing

Thaw in fridge (takes 2.5 hours)
or
Thaw at room temperature (takes 1 hour)

After thawing, let stand at room temperature for 15 minutes before administering.

Do not refreeze thawed vials.

Thaw in fridge (takes 2 hours)
or
Thaw at room temperature (takes 45 minutes) 

After thawing, let stand at room temperature for 15 minutes before administering.

Do not refreeze thawed vials.

Stability in Refrigerator
(2°C to 8°C)

Up to 30 days prior to first use 

Dilution

DO NOT DILUTE  

Stability at Room Temperature (up to 25°C)

No more than 24 hours 

Vials can be returned to fridge but time at room temperature must be tracked and not exceed 24 hours total.

Stability after
1st Puncture

Up to 24 hours at 2°C to 25°C

Vials can be returned to fridge but must track time at room temperature and not exceed 24 hours total. 

Time at room temperature includes any time at room temperature prior to puncture.

Do not puncture more than 20 times.

Protect from Light

Store in original carton.

Thawed vials and filled syringes can be handled in room light conditions. 

Handling

Swirl vial gently after thawing
and between each withdrawal.
Do not shake.

Appearance

White to off-white dispersion—may contain white or translucent product-related particles; ensure no foreign particulate matter or discolouration.

Clinical Information

Moderna Spikevax™
Red Cap,
Blue Border

Moderna Spikevax™ Bivalent
Royal Blue Cap,
Green Border

Dosage for Primary Series

≥ 6 years to <12 years:
0.25 mL (50 mcg mRNA)

≥ 12 years:
0.5 mL (100 mcg mRNA)

This vaccine is not authorized to be used as a primary COVID-19 immunization series. However, the SK Ministry of Health supports permissive administration of bivalent vaccines for this purpose, with informed consent, if an individual requests to start or complete their COVID-19 primary series with bivalent vaccine.

See information for original vaccines in the Saskatchewan Immunization Manual for details of intervals.

#Doses in Primary Series

Number of doses to complete the primary series:
2 for non-immunocompromised; 3 for immunocompromised

Minimum Interval Between 1st and 2nd Doses (used to determine validity)

21 days per NACI 

Authorized  Interval Between 1st and 2nd Doses

28 days 

MoH Minimum Interval Between 1st and 2nd Doses

28 days

Optimal Interval

The optimal interval between 1st and 2nd doses per NACI and MoH is 8 weeksb 

Booster Doses Find information about doses, eligibility and intervals here.
Route of Administration Intramuscular (deltoid preferred) 
MoH = Ministry of Health; NACI = National Advisory Committee on Immunization

a. In SK, Moderna Spikevax™ Bivalent is the preferred bivalent vaccine for immunocompromised individuals, including those 12 to <18 years of age, in which case it is off-label.

b. There is evidence that longer intervals between the first and second doses of COVID-19 vaccines result in a more robust and durable immune response and higher vaccine effectiveness. Local transmission of the SARS-CoV-2 virus, the degree of individual risk of exposure to the virus, and the need of a second dose for earlier protection should be considered when deciding the interval. People who completed their primary vaccine series using manufacturer-authorized intervals also have very good protection against severe COVID-19 disease and do not need to restart their vaccine series.

References
Last updated

01 Nov 2022

By Vaccine Type (Original vs. Bivalent)

 

Pfizer-BioNTech 
Comirnaty®
Orange Cap, 
Orange Border

Pfizer-BioNTech 
Comirnaty®
Purple Cap,
Purple Border

Pfizer-BioNTech 
Comirnaty®
Grey Cap, 
Grey Border

Moderna Spikevax™
Red Cap,
Blue Border

DILUTE BEFORE USE  DO NOT DILUTE  
Authorized Ages ≥ 5 Years to < 12 Years ≥12 Years  ≥ 6 Years
Concentration 10 mcg / 0.2 mL 30 mcg / 0.3 mL  100 mcg / 0.5 mL
DIN 02522454 02509210 02527863 02510014
Packaging

Multidose preservative-free vials containing 10 doses

Cartons of 10 and 195 vials

Orange cap; orange border on label

Multidose preservative-free vials containing 6a doses

Cartons of 25 and 195 vials

Purple cap; purple border on label

Multidose preservative-free vials containing 6a doses

Cartons of 10 and 195 vials

Grey cap; grey border on label 

Multidose preservative-free 5 mL vials

Cartons of 10 vials

Red cap; blue border on label

Storage/Stability
Pfizer-BioNTech 
Comirnaty®
Orange Cap, 
Orange Border
Pfizer-BioNTech 
Comirnaty®
Purple Cap,
Purple Border
Pfizer-BioNTech 
Comirnaty®
Grey Cap, 
Grey Border
Moderna Spikevax™
Red Cap,
Blue Border
Stability in Freezer

Store at -90°C to -60°C (ultrafreezer) for up to 12 months from date on label. (Formerly 9 months)

Date on label is the date of manufacture.

Do not store at -25°C to -15°C.

Store at -90°C to -60°Cb (ultrafreezer) until the expiry date printed on the label. These dates have been extended for some product.c

Store at -25°C to -15°C for up to 2 weeks.d 

Store at -90°C to -60°C (ultrafreezer) for up to 12 months from date on label.

Date on label is the date of manufacture.

Do not store at -25°C to -15°C.
Store at -50°C to -15°C (freezer) until the expiry date printed on the label. 
Thawing

Thaw undiluted product in fridge (takes up to 4 hours)
or
Thaw undiluted product at room temperature (takes ~30 minutes)

Do not refreeze thawed vials.

Thaw undiluted product in fridge (takes up to 3 hours)
or
Thaw undiluted product at room temperature (takes ~30 minutes)

Do not refreeze thawed vials.

Thaw in fridge (takes up to 6 hours)
or
Thaw at room temperature (takes ~30 minutes)

Do not refreeze thawed vials.

Thaw in fridge (takes 2.5 hours)
or
Thaw at room temperature (takes 1 hour)

After thawing, let stand at room temperature for 15 minutes before administering.

Do not refreeze thawed vials.

Stability in Refrigerator
(2°C to 8°C)

Undiluted product: up to 10 weeks

Undiluted product: up to 31 days

Up to 10 weeks prior to first use 

Up to 30 days prior to first use 

Dilution

Dilute thawed vials once they have reached room temperature with 1.3 mL of sterile 0.9% Sodium Chloride Injection, USP.

Dilute thawed vials once they have reached room temperature with 1.8 mL of sterile 0.9% Sodium Chloride Injection, USP.

DO NOT DILUTE  

Stability at Room Temperature (up to 25°C)

Prior to dilution, no more than 12 hours 

After dilution, use within 12 hours from time of dilution.e  

(Time is additive: up to 24 hours at room temperature)

Prior to dilution, no more than 2 hours (including any thaw time)

After dilution, use within 6 hours from time of dilution.

(Time is additive: up to 8 hours at room temperature)

Prior to puncture, no more than 12 hours

After puncture, use within 12 hours of puncture.f

 (Time is additive: up to 24 hours at room temperature) 

No more than 24 hours 

Vials can be returned to fridge but time at room temperature must be tracked and not exceed 24 hours total.

Stability after
1st Puncture
Up to 12 hours at 2°C to 25°Cf Up to 6 hours at 2°C to 25°C 

Up to 12 hours at 2°C to 25°C f 

Up to 24 hours at 2°C to 25°C

Vials can be returned to fridge but must track time at room temperature and not exceed 24 hours total. 

Time at room temperature includes any time at room temperature prior to puncture.

Do not puncture more than 20 times.

Protect from Light

Store in original carton.

Vials can be handled in room light conditions after dilution.

Store in original carton.

Thawed vials can be handled in room light conditions.

Store in original carton.

Thawed vials and filled syringes can be handled in room light conditions. 

Handling

Invert gently 10 times during reconstitution.
Do not shake.

Before use, mix by inverting vaccine vial gently 10 times.
Do not shake.

Swirl vial gently after thawing
and between each withdrawal.
Do not shake.

Appearance

BEFORE dilution: thawed suspension may contain white to off-white opaque amorphous particles.

AFTER dilution: white to off-white suspension; ensure no particulate matter/discolouration.

BEFORE dilution: thawed suspension may contain white to off-white opaque amorphous particles.

AFTER dilution: off-white suspension; ensure no particulate matter/ discolouration.

BEFORE inverting: may contain white to off-white opaque amorphous particles.

AFTER inverting: white to off-white suspension; ensure no visible particles/ discolouration.

White to off-white dispersion—may contain white or translucent product-related particles; ensure no foreign particulate matter or discolouration.

Clinical Information
Pfizer-BioNTech 
Comirnaty®
Orange Cap, 
Orange Border
Pfizer-BioNTech 
Comirnaty®
Purple Cap,
Purple Border
Pfizer-BioNTech 
Comirnaty®
Grey Cap, 
Grey Border

Moderna Spikevax™
Red Cap,
Blue Border

Dosage for Primary Series 0.2 mL (10 mcg mRNA) 0.3 mL (30 mcg mRNA)  

≥ 6 years to <12 years:
0.25 mL (50 mcg mRNA)

≥ 12 years:
0.5 mL (100 mcg mRNA)

#Doses in Primary Series

Number of doses to complete the primary series:
2 for non-immunocompromised; 3 for immunocompromised

Minimum Interval Between 1st and 2nd Doses (used to determine validity) 19 days per NACI   

21 days per NACI 

Authorized  Interval Between 1st and 2nd Doses 21 days    

28 days 

MoH Minimum Interval Between 1st and 2nd Doses 28 days (21 days is acceptable)  

28 days

Optimal Interval

The optimal interval between 1st and 2nd doses per NACI and MoH is 8 weeksg 

Booster Doses Find information about doses, eligibility and intervals here.
Route of Administration Intramuscular (deltoid preferred)      
MoH = Ministry of Health; NACI = National Advisory Committee on Immunization

a. Six doses can be achieved by using low dead-volume syringes and/or needles. If standard syringes and needles are used, there may not be sufficient volume to extract 6 full doses from a single vial. 

b. On August 27, 2021, Health Canada expanded the Ultra Low Temperature storage conditions to now allow storage at -90°C to -60°C (-130°F to -76°F) versus the previously approved -80°C to -60°C (-112°F to -76°F). All references to storage conditions of -80°C to -60°C (-112°F to -76°F) on cartons and supporting printed material currently in Canada should now be considered between -90°C to -60°C (-130°F to -76°F.

c. Extensions to expiry dates for Pfizer-BioNTech Comirnaty® Purple Cap only (not Orange Cap or Grey Cap), as long as all approved storage conditions have been maintained, include:

  • Products with labelled expiry date of Jun 2022 through August 2022 may remain in use for 3 months beyond printed date.
Printed Expiry Date Updated Expiry Date
August 2022 November 2022

d. Vials stored/transported at -25°C to -15°C for up to 2 weeks may be returned (once) to the recommended storage condition of -90°C to -60°C. Total time the vials are stored and /or transported at -25°C to -15°C must be tracked and not exceed 2 weeks.

e. Vial labels and cartons may state that a vial should be discarded 6 hours after dilution; however, additional testing has been completed to support 12 hours of stability after dilution.

f. Vial labels and cartons may state that a vial should be discarded 6 hours after puncture; however, additional testing has been completed to support 12 hours of stability after puncture.

g. There is evidence that longer intervals between the first and second doses of COVID-19 vaccines result in a more robust and durable immune response and higher vaccine effectiveness. Local transmission of the SARS-CoV-2 virus, the degree of individual risk of exposure to the virus, and the need of a second dose for earlier protection should be considered when deciding the interval. People who completed their primary vaccine series using manufacturer-authorized intervals also have very good protection against severe COVID-19 disease and do not need to restart their vaccine series.

References
Last updated

01 Nov 2022

 

Moderna Spikevax™ Bivalent
Royal Blue Cap,
Green Border

Pfizer-BioNTech 
Comirnaty® Original & Omicron BA.4/BA.5
Grey Cap, Grey Border

DO NOT DILUTE  
Authorized Ages ≥ 18 Yearsa ≥12 Years 
Concentration 50 mcg / 0.5 mL
(25 mcg each Original and Omicron BA.1)

30 mcg / 0.3 mL
(15 mcg each Original and Omicron BA.4/BA.5)

DIN 02530252 02531461
Packaging

Multidose preservative-free 2.5 mL vials

Cartons of 10 vials

Royal blue cap; green border on label

Multidose preservative-free vials containing 6b doses

Cartons of 10 vials

Grey cap; grey border on label 

Storage/Stability
Moderna Spikevax™ Bivalent
Royal Blue Cap,
Green Border

Pfizer-BioNTech 
Comirnaty® Original & Omicron BA.4/BA.5
Grey Cap, Grey Border

Stability in Freezer Store at -50°C to -15°C (freezer) until the expiry date printed on the label. 

Store at -90°C to -60°C (ultrafreezer) for up to 12 months from date on label.

Date on label is the date of manufacture.

Do not store at -25°C to -15°C.
Thawing

Thaw in fridge (takes 2 hours)
or
Thaw at room temperature (takes 45 minutes) 

After thawing, let stand at room temperature for 15 minutes before administering.

Do not refreeze thawed vials.

Thaw in fridge (takes up to 6 hours)
or
Thaw at room temperature (takes ~30 minutes)

Do not refreeze thawed vials.

 

Stability in Refrigerator
(2°C to 8°C)

Up to 30 days prior to first use 

Up to 10 weeks prior to first use 

Dilution

DO NOT DILUTE  

Stability at Room Temperature (up to 25°C)

No more than 24 hours 

Vials can be returned to fridge but time at room temperature must be tracked and not exceed 24 hours total.

Prior to puncture, no more than 12 hours

After puncture, use within 12 hours of puncture.

 (Time is additive: up to 24 hours at room temperature) 

Stability after
1st Puncture

Up to 24 hours at 2°C to 25°C

Vials can be returned to fridge but must track time at room temperature and not exceed 24 hours total. 

Time at room temperature includes any time at room temperature prior to puncture.

Do not puncture more than 20 times.

Up to 12 hours at 2°C to 25°C

Protect from Light

Store in original carton.

Thawed vials and filled syringes can be handled in room light conditions. 

Store in original carton.

Thawed vials can be handled in room light conditions.

Handling

Swirl vial gently after thawing
and between each withdrawal.
Do not shake.

Before use, mix by inverting vaccine vial gently 10 times.
Do not shake.

Appearance

White to off-white dispersion—may contain white or translucent product-related particles; ensure no foreign particulate matter or discolouration.

BEFORE inverting: may contain white to off-white opaque amorphous particles.

AFTER inverting: white to off-white suspension; ensure no visible particles/ discolouration.

Clinical Information

Moderna Spikevax™ Bivalent
Royal Blue Cap,
Green Border

Pfizer-BioNTech 
Comirnaty® Original & Omicron BA.4/BA.5
Grey Cap, Grey Border
 

Dosage for Primary Series

 

 

These vaccines are not authorized to be used as a primary COVID-19 immunization series. However, the SK Ministry of Health supports permissive administration of either bivalent vaccine for this purpose, with informed consent, if an individual requests to start or complete their COVID-19 primary series with bivalent vaccine.

See information for original vaccines in the Saskatchewan Immunization Manual for details of doses and intervals.

#Doses in Primary Series
Minimum Interval Between 1st and 2nd Doses (used to determine validity)
Authorized  Interval Between 1st and 2nd Doses
MoH Minimum Interval Between 1st and 2nd Doses
Optimal Interval
Booster Doses Find information about doses, eligibility and intervals here.
Route of Administration Intramuscular (deltoid preferred) 
MoH = Ministry of Health; NACI = National Advisory Committee on Immunization

a. In SK, Moderna Spikevax™ Bivalent is the preferred bivalent vaccine for immunocompromised individuals, including those 12 to <18 years of age, in which case it is off-label.

b. Six doses can be achieved by using low dead-volume syringes and/or needles. If standard syringes and needles are used, there may not be sufficient volume to extract 6 full doses from a single vial.  

References
Last updated

01 Nov 2022